Roche Extends Offer Period for Spark Therapeutics
April 03 2019 - 1:50AM
Dow Jones News
By Pietro Lombardi
Roche Holding AG (ROG.EB) and Spark Therapeutics Inc. (ONCE)
said Wednesday that Roche is extending the offer period for Spark
after it withdrew the premerger notification and report form
related to the acquisition.
The move comes under the Hart-Scott-Rodino Act, the companies
said, and Roche intends to refile around April 10.
"As a result of the withdrawal and refiling of the premerger
notification and report form, Roche is extending the offering
period of its previously announced tender offer to purchase all of
the outstanding shares of common stock of Spark," the companies
said.
The offer now expires on May 2.
As of April 2, roughly 29.4% of Spark's outstanding shares had
been tendered.
Write to Pietro Lombardi at pietro.lombardi@dowjones.com
(END) Dow Jones Newswires
April 03, 2019 01:35 ET (05:35 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Roche (QX) (USOTC:RHHBY)
Historical Stock Chart
From Apr 2023 to Apr 2024
